On September 14, WUXI BIO rose 3.06% in regular trading, trading at 48.46 HKD/share, with turnover of approximately 3.51 billion HKD. The gain came amid a broad rally across the Life Sciences Tools and Services sector.

The CXO and innovative drug sectors are experiencing a valuation recovery, with multiple brokerages confirming bottom-formation signals. Peers including PHARMARON rose 5.74%, WUXI APPTEC gained 3.28%, and GENSCRIPT BIO climbed 3.52%. The collective strength was underpinned by robust industry fundamentals, with CXO revenue across HK-listed names growing 29.2% in the first half, the fastest among all pharmaceutical sub-sectors.

On the company level, WUXI BIO reported H1 revenue of 11.787 billion yuan, up 18.4% year-over-year, while adjusted net profit attributable to shareholders surged 38.4%. The company raised its full-year guidance, with backlog reaching approximately USD 5.5 billion, up around 30% year-over-year. Additionally, the broader buyback program totaling up to approximately 5.5 billion yuan has provided share price support. Multiple investment banks, including CICC and CMBI, recently raised their target prices to 60 HKD, maintaining buy ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)